Enterprise League logo

Biotechnology Companies in Europe

Biotechnology companies develop, manufacture, and distribute medical devices, diagnostics, or pharmaceutical products for use in clinical, hospital, and research settings. This page lists companies operating in the Biotechnology sector based on self-reported profile data. The directory currently holds 480 companies in this sector. The largest share of listings is based in London. Related sectors on Enterprise League include Medical Equipment and Services, Life Science, Genetics, Pharmaceutical, Biopharma, Clinical Trials, Nanotechnology.
480 companies
London top city

Europe
Biotechnology
List of Biotechnology companies in Europe

480 companies

Sort by

Secure, transparent compression for genomic data. PetaGene helps organisations manage their rapidly growing genomic data using transparent lossless compression and encryption. PetaGene's multi award-winning software significantly reduces storage and access costs, accelerates transfers and analyses, and simplifies cloud integration for genomic data. It also helps manage compliance through encryption and deep auditing. Large pharma, commercial, clinical and academic labs use PetaGene to cut costs, reduce turn-around times, and add new capabilities to their genomic workflows without disruption to their users or technology framework. For more information, please visit: https://www.petagene.com
Biotechnology

2016

Stemnovate provides innovative technologies for drug screening and safety testing. We have developed state of the art platform technologies, underpinned by experience in tissue procurement, cell biology, high through put imaging and microfluidics. We provide a customer friendly and flexible platform for human drug discovery which overcome many of the limitations associated with mammalian cell lines and in vivo models.
Biotechnology

2016

Somos una empresa pionera y líder en la fabricación de diluyentes, materiales y automatización de procesos para la Inseminación Artificial Animal. Germinado en el Instituto de Investigación, INIA, nos constituimos como empresa en febrero de 1986 y desde el inicio con vocación global, hoy exportamos a más de 55 países. Nuestros diluyentes para semen porcino son reconocidos a nivel mundial por su alta calidad y alta protección espermática. Nos esforzamos en la formación y divulgación del progreso en las técnicas de IA. KUBUS S.A. is a pioneer Spanish biotechnology company and leader in the manufacture of extenders, consumables, equipment and supplements for Animal Artificial Insemination. The company was established in February 1986 and since its foundation has exported its products to more than 55 countries. Our extenders are recognized worldwide for its high quality. Since its foundation KUBUS has focused its efforts on improving and disseminating the advancement in assisted reproduction and hundreds of professionals have trained with us and spread the technique in all parts of the world. We are proud of the history of this company and we invite all those people who want to contribute their knowledge in the improvement of reproduction techniques to get in touch with us.
Biotechnology

1986

Proteon Pharmaceuticals S.A. uses precision biology for microbiome modulation to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. PROTEON's products improve the economic efficiency in livestock farming and aquaculture, increasing environmental sustainability with natural products that also enhance animal welfare.
Biotechnology

2005

Discovery Park is the ideal environment for life science businesses to succeed. From state-of-the-art labs and offices to comprehensive support, we work in partnership with you to provide firm foundations for every stage of your growth. Within easy reach of London, our location provides access to a wealth of resources and opportunities with the freedom to expand, making it the optimal setting for brilliant minds to unlock the potential of scientific breakthroughs.
Biotechnology

2012

uFraction8 builds products around a disruptive new liquid particle processing technology. Following our world leading research, establishing new levels of throughput for massively multiplexed microfluidic devices, our technology will be the key to unlock a prosperous and sustainable future. Our technology offers superior performance and cost savings against the big three liquid processing technologies of filtration, flow centrifugation and flocculation. High volume applications benefit by our unique ability to granularly match targeted volumetric throughputs and our ability to scale this beyond the physical limitations of competing technologies. Maintaining an unobstructed flow path allows our technology to continue operation in even high suspended solid applications, with operation up to 46% volume fraction maintaining 99.6% +/-0.3% efficiency. Recovery of targeted particles is not hampered by penetration into pores, allowing unmatched recovery from low initial concentration. Particles can be selected out by size with single digit micron precision to ensure only those of interest are extracted, simplifying any subsequent detection or processing. Our planned products will benefit the world in substantial ways, enhancing food security, increasing access to medicines and nutrients, preserving ocean life and enhancing operational capabilities of humanitarian aid missions. Beginning our journey, developments are focusing on the most immediately impactful area of sustainable bioproduction. Hampered by the high costs of downstream processing from closed bioreactor systems, our products energy efficiency, non-dependence on consumables or pre-concentration and scalability will unlock economies of scale to achieve dramatic increase in global biomass production. Made with SS316L wettable components, customers using fresh or saltwater producing acids, bases, solvents and aromatics can safely scale their production capabilities and drastically reduce their costs.
Biotechnology

2017

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.
Biotechnology

2017

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.
Biotechnology

2016

Cell aging is the underlying driver of modern diseases and therefore cell rejuvenation provides one of the greatest opportunities in drug development. Shift has built proprietary datasets that uncover the hidden biology of cell aging and rejuvenation, revealing single genes that rejuvenate multiple cell types with improved safety, small molecule targets and a connection to fibrosis. This raises the prospect of lifespan-impacting therapeutics developed for age driven indications.
Biotechnology

2017

We have set out to revolutionise the field of personalised cancer diagnostics by providing AI-driven point-of-care solutions to improve clinical outcomes in cancer patients. Our vision extends beyond this, as we aim to unlock point-of-need personalised diagnostics solutions for medical professionals and individuals alike within various medical domains.
Biotechnology

2018

With more than twenty years of hands-on experience in pharmaceutical, cosmetic and food biotech industry, our scientists and technical staff developed skills ranging from microbial fermentation process development, to process scale up and recovery of products. Biosphere provides qualified contract R&D and manufacturing services for the production of microbial biomass, enzymes and metabolites. Biosphere collaborates with companies, universities, research institutes and scientific networks in several research projects, with private or public funding. The contract R&D service is mainly addressed to the study of new enzymes for the pharmaceutical sector, the improvement and innovation of traditional products and valorisation of by-products in the food and feed sectors, the study of innovative solutions in the field of green chemistry and renewable energy.
Biotechnology

1998

Oxitec is a team of passionate individuals from 15 countries improving lives and livelihoods by developing the world's first safe, self-limiting technology to control pests that transmit diseases, destroy crops and harm livestock. Our technology platform allows us to build safe, non-toxic, species-specific, and self-limiting control solutions to a range of damaging insects. We work in close partnerships with governments, foundations, companies and communities around the world and have demonstrated excellence in targeted insect suppression, biosafety, environmental sustainability, regulatory approvals, public acceptance, and scalability. We are growing, so people who share our desire to have impact globally are encouraged to get in touch.
Biotechnology

2002

Chr. Hansen has combined with Novozymes to become Novonesis: linkedin.com/company/novonesis. This global biosolutions company of 10,000 people is transforming how the world produces, consumes and lives. In 30-plus industries, its biosolutions help businesses meet their needs and the needs of our planet. Chr. Hansen was founded in 1874 by the Danish pharmacist Christian D. A. Hansen who invented an industrial process to extract rennet for cheese making. The company was a microbial powerhouse that developed natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. Its unique microbial and fermentation technology platforms and collection of around 50,000 microbial strains helped it meet its commitment to grow a better world. Naturally. In December 2022, Chr. Hansen and Novozymes entered into an agreement to create a leading global biosolutions partner by combining the two companies. The goal was to unleash the full potential of biosolutions and generate significant value for all stakeholders and society. The combination was completed on January 29, 2024, and Novonesis was born. The name means ‘a new beginning’ and is derived from the Greek word ‘genesis’. It reflects a new era where we’ll better our world with biology. You can find Novonesis on LinkedIn here: linkedin.com/company/novonesis. Chr. Hansen A/S, part of Novonesis Group.
Biotechnology

1874

BIOMED LAB is the first private laboratory for molecular diagnostics in Macedonia. The laboratory is equipped with modern equipment which enables fast and accurate results for molecular diagnostic methods. Our commitment is to provide fast, accurate and adjusted genetic testing, improving our capabilities and expertise to keep up with new technologies, and maintaining our dedication to quality. The team daily works to increase the number of new analyzes in accordance with the most sophisticated methods in the field. Within the laboratory exists and Research Department for analyzing important biological processes on a molecular level in order to improve human health. Also, BIOMED LAB performs laboratory and consultative - professional services.
Biotechnology

2013

Developing a blood-based DNA methylation test for early cancer detection leveraging the latest technology in DNA methylation testing and AI classification
Biotechnology

2023

Iribov is an international plant breeding support laboratory founded in 1992, employing around 600 people in 4 locations: in The Netherlands (Heerhugowaard), Macedonia (Vinica), Ghana (Sogakope) and Brasil. The services of Iribov can be divided into 4 segments: 𝗣𝗹𝗮𝗻𝘁 𝗧𝗶𝘀𝘀𝘂𝗲 𝗖𝘂𝗹𝘁𝘂𝗿𝗲: Initiation, Virus Elimination, Naktuinbouw Elite certified production, Stock Maintainance, Protocol Development, Large Scale Propagation. 𝗕𝗿𝗲𝗲𝗱𝗶𝗻𝗴 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: Gene Bank Storage in Tissue Culture, Interspecific crossing, Embryo Rescue, Mutation Induction, Dihaploid production, Polyploidization, Marker Assisted Breeding, Crispr-Cas (future development). 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀: Plant pathogen detection (PCR), Seed quality control, Flowcytometry, Cytology, Biochemical Assays, Bioassays. Hardening: automated planting of tissue culture plants, vertical farm facilities, automated grading and sorting, various growing compartments and -specifications, tailor made growing solutions. The portfolio of Iribov covers over 450 plant species in 10.000 varieties for the ornamental horticulture, vegetable and (soft)fruit companies and the plantation industry worldwide.
Biotechnology

1992

Established in 1997, Ergomed is a global leader in delivering specialized services in oncology, rare disease, and complex trials to the pharmaceutical and biotech sectors. Our comprehensive support covers the entire clinical trial process, from early phase to post-approval, offering full-service, industry-leading clinical trial management solutions as a trusted partner. Our integrated service model helps life sciences companies meet regulatory obligations, maximize drug development success, and enhance the patient experience.
Biotechnology

1997

Sqilline Health is transforming cancer care by turning complex clinical data into actionable evidence. Using large language models (LLMs) and AI-powered structuring, we unlock the full potential of oncology data — enabling better patient outcomes. We partner with life sciences and healthcare providers to accelerate research, improve outcomes, and ensure that no one faces cancer alone — not patients, nor physicians. At Sqilline Health, our mission is to bring clarity to cancer care. For more information, visit sqilline.com and follow us on LinkedIn.
Biotechnology

2009

For more than a decade the Tentamus Group has been providing services to customers all over the world. Our quality and safety services focus on the testing, auditing and consulting of products that influence human well-being from within. The Tentamus Group is valued by many companies as a true service partner for a wide range of products with a high degree of quality and local understanding. More than 90 laboratories with more than 4,000 highly qualified employees are part of the Tentamus Group worldwide. Regardless of the size of our group, we pride ourselves on providing tailor-made services to each of our customers, and we are honoured by their rapidly growing trust.
Biotechnology

2011

Delivering AnalytiXagility, the trusted, secure, self-service, cloud-enabled digital research environment for biomedical, precision medicine and healthcare researchersAnalytiXagility delivers secure, auditable workspaces for research teams to engage personally, collaboratively and productively around data from multiple systems and sources in order to address complex data challenges.
Software
Biotechnology

2007

AXELEROS Preclinical Development is a Brussels-based preclinical development consultancy specializing in regulatory affairs and preclinical study management for the biopharmaceutical industry.

We support clients – including biotech companies, SMEs, and research institutions – throughout the entire preclinical process, from initial strategic planning to regulatory submission. Our team provides expert guidance on navigating the complex landscape of global regulations, ensuring your innovations meet the highest standards and accelerate their journey to market.

Our core services encompass a comprehensive suite of offerings, including strategic regulatory planning, global regulatory submissions, sourcing and management of toxicology and pharmacology studies, and toxicological risk assessments. We are dedicated to helping you bring your groundbreaking therapies to patients worldwide. We also offer European Public Affairs support to unlock valuable funding opportunities for your healthcare projects.
Biopharma
Biotechnology
Life Science
EpiXlife is a biotechnology company based in Valencia, Spain, specializing in innovative wellness solutions for healthcare professionals.

We empower professionals across Argentina, Brazil, Colombia, Mexico, Spain, and Uruguay with cutting-edge technologies and personalized training.

EpiXlife distinguishes itself through its integrated approach, combining advanced bioprobes, comprehensive training programs, and targeted marketing strategies, all supported by ongoing expert support. We are dedicated to transforming the wellness industry and helping professionals maximize their impact on patient lives.

Our mission is to provide professionals with the tools and knowledge they need to thrive in a rapidly evolving landscape, fostering a future where wellness is accessible and effective for all.
Biopharma
Biotechnology
Life Science

2019

CNRS UMR8199 is a French research institute based in Lille, specializing in the study of metabolic diseases and their genetic causes.

Our team, led by Pr. Philippe Froguel, focuses on understanding the molecular mechanisms behind diseases like diabetes and obesity, with the ultimate goal of developing more effective prevention and treatment strategies.

We conduct cutting-edge research in genomics and molecular physiology, contributing to a deeper understanding of these complex conditions and paving the way for personalized medicine. We are a key player in the **biotechnology research** sector, collaborating with leading institutions globally.

Established in 1995, CNRS UMR8199 has grown to a team of 11 researchers, furthering our commitment to advancing scientific knowledge and improving patient outcomes.
Biopharma
Biotechnology
Life Science

1995

Orano Med is a French research and development company specializing in the production of high-purity lead-212 (Pb-212), a rare radioactive isotope, and driving innovation in targeted cancer therapies.

Based on a program initiated in 2005, Orano Med has pioneered the targeted alpha therapy (TAT) approach, recognizing and destroying cancer cells while minimizing harm to healthy tissue.

Leveraging Macrocyclics, Inc., a key component of Orano Med, the company operates a robust industrial platform for Pb-212 production and maintains a strong pipeline of research and development, including 18 clinical trials and over 30 patents.

With 220 employees across France and the United States, Orano Med is committed to advancing the field of nuclear medicine and improving patient outcomes through cutting-edge radiotherapeutic solutions.
Biopharma
Biotechnology
Life Science
Iktos is a Paris, France-based artificial intelligence company revolutionizing drug discovery.

We specialize in applying generative AI to medicinal chemistry, enabling pharmaceutical companies and research institutions to design and optimize molecules in silico. Our proprietary SaaS platforms, Makya™ and Spaya™, combined with our AI-driven robotics platform, dramatically accelerate the entire drug development process – from initial design to synthesis and testing.

Iktos is at the forefront of innovation, leveraging cutting-edge technology to reduce R&D timelines and increase the success rate of new drug candidates, particularly in oncology and autoimmune diseases. We are proud to have received significant investment and recognition, including a recent EIC Accelerator grant, demonstrating our commitment to transforming the future of drug discovery.
Biopharma
Biotechnology
Life Science

2016

is a preclinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders.
Health and Medical Products
Laboratories
Biotechnology

2016

Scindo is a cleantech start-up harnessing the power of enzymes to recycle the unrecyclables. We are targeting plastics that cannot be efficiently recycled with current methodologies, to turn them into high-value molecules that can be used in a plethora of industries. We are creating a more circular economy for plastics by developing an alternative to landfills and incineration.
Recycling
Biotechnology

2020

Celtic Renewables Limited is an innovative and award-winning company formed to commercialise a process for producing a superior next-generation biofuel (and other high-value sustainable products) from the by-products of biological industries. Further information at www.celtic-renewables.com Follow us on Twitter @CRL_UK Follow us on Facebook @celticrenewables Follow us on Instagram @celticrenewables
Manufacturing
Renewable Energy
Innovation Management
Biotechnology

2012

Over 10 million people around the world are suffering with stiffness and slowness caused by Parkinson’s Disease. CUE1, a focused vibrotactile stimulation device, has granted all of the pilot participants improved movement. Participants claimed that they felt their movement was smoother and better coordinated when using the device.
Wellness and Spa
Exercise and Fitness
Healthcare
Biotechnology

2019

Harnessing the power of deep learning on 3D molecular configurations to deliver medicines of transformational efficacy to patients.
Market Research
Artificial Intelligence
Biotechnology
Life Science

2021

Ambiotis is a pre-clinical CRO specialized in the study of inflammatory processes and the active end of inflammation, called resolution. Resolution is now recognized as the necessary biological process to stop inflammation and restore homeostasis in tissues. This recent approach makes possible to study the inflammation process in a completely innovative and differentiating way. Ambiotis proposes services adapted to pharmaceutical, dermo-cosmetic, agro- food/nutraceutical industries to evaluate the potential of their molecules at preclinical or clinical stages of development. Ambiotis thus helps them to put faster on the market more efficient and innovative compounds on immuno-inflammatory processes. With more than 10 years of experience, Ambiotis has acquired a solid expertise in understanding the molecular mechanisms controlling these phenomenons . Ambiotis has built a strong expertise in both cell/animal models and analytical measurement. This combination is the key to ensure a full understanding and provide proof of efficacy or proof of concept for the development of new innovative products.
Biotechnology
Science-enabled Precision Oncology
Healthcare
Biotechnology

2015

deepmatter® is a chemical data company that liberates chemists to capture, record and discover together on a global scale with our range of products: DigitalGlassware® brings recordability, reproducibility and shareability to your lab at every stage of the discovery process, from planning your chemistry to analysing the outcome. ICSYNTH is a synthesis design tool that enables chemists to generate synthetic pathways for target molecules, stimulating ideas for alternative or novel synthetic routes that otherwise may not be considered. Our Mining for Chemistry offering helps you to annotate structures and semantically enrich your Chemistry and Life Sciences documents and data. deepmatter® also offers a broad selection of software tools and applications to solve any problem in the field of chemical data management, focusing in particular on high performance and reliability in handling and management of large chemical data sets. All deepmatter® solutions are very flexible and can therefore be integrated into customer pre-existing infrastructures, which is an important aspect as research organizations design more comprehensive and integrated environments for successful discovery.
Market Research
Product Design
Software
Analytics Analysis
Pharmaceutical
Biotechnology

2015

Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
Pharmaceutical
Biotechnology
Life Science

2019

Holiferm is bringing biosurfactants to market and is in the process of building a ktonne scale sophorolipid manufacturing plant.
Industrial Services
Industrial Engineering
Pharmaceutical
Biotechnology

2018

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.
Artificial Intelligence
Medical
Biopharma
Healthcare
Biotechnology

2014

Atrandi Biosciences is breaking new ground in high-throughput analysis technologies. Providing simple-to-adopt and easy-to-use droplet microfluidics and high-throughput screening (HTS) workflows. Droplet microfluidics technology is at the core of our products and provides an unmatched platform for exploring the complexity of biology in a high-throughput manner. Droplet microfluidics enables compartmentalizing molecular biology reactions into millions of pico-liter droplets, empowering you to study biological samples at the resolution of single cells and single molecules. Our work is at the intersection of life sciences, engineering, and machine learning. We deliver elegant solutions and novel tools for groundbreaking high-throughput research by integrating different technologies.
Biotechnology
Pharmaceutical
Life Science

2016

Apitope is a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases. We use our novel, proprietary discovery platform to select and develop highly specific peptide-based therapies, known as “apitopes®”, which restore the natural balance (immune tolerance) of the immune system. This mechanism of action avoids global immune suppression and has the broad potential to treat a wide variety of autoimmune diseases. Apitope’s lead product candidate ATX-MS-1467 is in clinical development for treating multiple sclerosis (“MS”). ATX-MS-1467 is the first potential therapeutic for MS that combines high efficacy with an excellent, and thereby differentiating, safety profile. Apitope’s other lead product candidate ATX-GD-59 demonstrates potential to be the first disease-modifying treatment for Graves' disease and the first potential innovative treatment for the disease in more than 60 years. In addition, Apitope has developed a robust pipeline with several innovative, potential first-in-class product candidates advancing towards clinical development for the treatment of, amongst other indications, uveitis, factor VIII inhibitors, myocarditis, and rheumatoid arthritis. Founded in 2002, Apitope has an experienced leadership team with a strong track record in the pharmaceutical industry and scientific community.
Medical
Healthcare
Biotechnology

2002

Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.
Medical
Healthcare
Biotechnology
Therapeutics

2021

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumours. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery and PARP inhibitors; key staff at Artios developed the drug olaparib (Lynparza ™). Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Medical Equipment and Services
Health and Medical Products
Biopharma
Biotechnology

2016

Biofidelity's mission is to enable the early detection of disease and to improve patient outcomes through the implementation of simple yet ultra-high sensitivity diagnostic assays based on our proprietary biochemistry. We have developed a novel molecular assay enabling the multiplexed detection of genetic mutations at extremely high sensitivity (<0.1% allele fraction) from tissue or blood samples, without the need for DNA sequencing. Using standard laboratory instrumentation, our assays are simple, fast, scalable and low-cost, enabling rapid implementation and broad adoption. The simplicity of this technology makes it particularly suited to routine testing applications, including patient monitoring for disease recurrence and developed resistance to therapy, and to early detection of disease.
Healthcare
Biotechnology
Genetics

2019

Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing novel therapeutics targeting free fatty acid receptors for NASH, Type 2 Diabetes (T2D) and other potential indications. Caldan has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow.
Biotechnology

2015

ENYO Pharma is a clinical stage company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. We develop new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology. Our main candidate Vonafexor (EYP001, FXR agonist) is in Phase 2 for both chronic hepatitis B and Non-Alcoholic Steato-Hepatitis. Our second candidate, EYP002, is currently in preclinical studies. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or metabolic diseases. Thanks to the MIMESIS project, funded by European Union’s Horizon 2020 Research and Innovation Program, ENYO Pharma has a portfolio of early molecules for various indications (RSV, Immunogenic Cell Death, Zika virus, rhinovirus, influenza virus and Mycobacterium tuberculosis) ENYO Pharma is also a member of the CARE consortium (Corona Accelerated R&D in Europe), the largest European research initiative addressing the drug discovery challenges of COVID-19, funded by IMI 2 JU. ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.
Biotechnology

2014

Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design.
IT Services
IT Consulting Services
Biotechnology
Life Science

2020

Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need. The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
Healthcare
Biotechnology

2017

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use. Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.
Pharmaceutical
Biotechnology

2008

Timeline (parent company Amazentis) is an innovative, dynamic and growing biotech company positioned in the nutrition and skin health sectors and is located in the multicultural region of Lausanne, Switzerland. Acting at the intersection of the food and pharma industries, Amazentis employs best-in-class science to discover and develop new products to increase longevity, manage specific health needs, and support an active lifestyle.
Wellness and Spa
Nutrition
Healthcare
Biotechnology

2007

Antag Therapeutics is based on years of collaborative research from the University of Copenhagen with the focus on novel treatments for dietary-related metabolic diseases. The research teams of professors Mette M. Rosenkilde and Jens J. Holst have discovered naturally occurring therapeutic peptides that are being investigated in several human studies.
Human Resources
Biotechnology
Therapeutics

2017

Aurum Biosciences Ltd is a clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS). Follow-on indications include heart disease, oncology, inflammatory conditions, spinal cord injury, and dementia. Preclinical development has been completed in the lead indication (AIS) and approval has been granted to initiate clinical studies in acute stroke patients. Concurrently, Aurum is pursuing opportunities to develop its pipeline indications with a focus on inflammatory conditions and oncology.
Pharmaceutical
Healthcare
Biotechnology

2015

Biolux Medical is biotechnology company that specializes in photomodulation.
IT Services
Medical Equipment and Services
Health and Medical Products
IT Consulting Services
Medical
Healthcare
Innovation Management

2007

List of Biotechnology companies in Europe

Company Name

Location

Category

Employees

Website

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

10-20

https://www.petagene.com/

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

http://www.stemnovate.co.uk

Las Rozas de Madrid, Spain

Science and Engineering
Science and Engineering

50-100

http://www.kubus-sa.com

Lodz, Poland

Science and Engineering
Science and Engineering

50-100

http://www.proteonpharma.com

Sandwich, United Kingdom (UK)

Science and Engineering
Science and Engineering

50-100

http://www.discovery-park.co.uk/

Falkirk, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

http://www.ufraction8.com

Cardiff, United Kingdom (UK)

Science and Engineering
Science and Engineering

20-30

https://www.antiverse.io/?utm_source=linkedin&utm_medium=social&utm_campaign=linkedin-homepage

Edinburgh, United Kingdom (UK)

Science and Engineering
Science and Engineering

200-500

http://www.roslinct.com

Cambridge, United Kingdom (UK)

Science and Engineering
Science and Engineering

20-30

https://shiftbioscience.com

London, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

http://hq-science.com

Forlì (Forlì-Cesena), Italy

Science and Engineering
Science and Engineering

20-30

http://www.biospheresrl.com

Oxford, United Kingdom (UK)

Science and Engineering
Science and Engineering

100-150

http://www.oxitec.com

Hørsholm, Denmark

Science and Engineering
Science and Engineering

5000+

http://www.novonesis.com

Ohrid, Macedonia

Science and Engineering
Science and Engineering

2-10

http://www.biomedlab.mk

Skopje, Macedonia

Science and Engineering
Science and Engineering

2-10

https://www.fingerprintdx.com/

Heerhugowaard, The Netherlands

Science and Engineering
Science and Engineering

500-1000

http://www.iribov.com

Guildford, United Kingdom (UK)

Science and Engineering
Science and Engineering

1000-5000

http://www.ergomedcro.com/

Berlin, Germany

Science and Engineering
Science and Engineering

20-30

http://www.sqilline.com

Berlin, Germany

Science and Engineering
Science and Engineering

1000-5000

https://www.tentamus.com

Glasgow, United Kingdom (UK)

Information Technology
+1
Information Technology, Science and Engineering

50-100

https://www.aridhia.com

Brussels, Belgium

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

http://www.axelerospreclinical.com

Valencia, Spain

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://www.epixlife.com

Lille, France

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

http://www-good.ibl.fr/

Villejuif, France

Health and Medical
+1
Health and Medical, Science and Engineering

150-200

http://www.oranomed.com

Paris, France

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

http://iktos.ai/

Zurich, Switzerland

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

http://endogena.com/

London, United Kingdom (UK)

Environment
+1
Environment, Science and Engineering

2-10

https://scindo.bio/

Edinburgh, United Kingdom (UK)

Manufacturing and Industry
+3
Manufacturing and Industry, Environment, Professional Services, Science and Engineering

50-100

https://www.celtic-renewables.com/

Cambridge, United Kingdom (UK)

Beauty and Personal Care
+3
Beauty and Personal Care, Sport and Recreation, Health and Medical, Science and Engineering

30-50

https://charconeurotech.com/

London, United Kingdom (UK)

Sales and Marketing
+2
Sales and Marketing, Information Technology, Science and Engineering

30-50

https://charmtx.com/

Toulouse, France

Science and Engineering
Science and Engineering

10-20

https://www.ambiotis.com/en/

Cupertino, Portugal

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.ophiomics.com/

Glasgow, United Kingdom (UK)

Sales and Marketing
+4
Sales and Marketing, Design Services, Information Technology, Health and Medical, Science and Engineering

20-30

https://www.deepmatter.io/

Copenhagen, Denmark

Health and Medical
+1
Health and Medical, Science and Engineering

20-30

https://hemab.com/

Manchester, United Kingdom (UK)

Manufacturing and Industry
+2
Manufacturing and Industry, Health and Medical, Science and Engineering

50-100

https://holiferm.com/

Cambridge, United Kingdom (UK)

Information Technology
+2
Information Technology, Health and Medical, Science and Engineering

50-100

https://healx.ai/

Vilnius, Lithuania

Science and Engineering
+1
Science and Engineering, Health and Medical

30-50

https://www.atrandi.com/

Bristol, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://apitope.com/

Berlin, Germany

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://ariceum-therapeutics.com/

Cambridge, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://www.artios.com/

Cambridge, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://biofidelity.com/

Edinburgh, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://www.caldantherapeutics.com/

Lyon, France

Science and Engineering
Science and Engineering

30-50

https://www.enyopharma.com/

Lausanne, Switzerland

Information Technology
+2
Information Technology, Business Services, Science and Engineering

10-20

https://www.adaptyvbio.com/

Copenhagen, Denmark

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://adcendo.com/

Leiden, The Netherlands

Health and Medical
+1
Health and Medical, Science and Engineering

20-30

https://www.amarnatherapeutics.com/

Lausanne, Switzerland

Beauty and Personal Care
+2
Beauty and Personal Care, Health and Medical, Science and Engineering

30-50

https://www.timelinenutrition.com/

Copenhagen, Denmark

Business Services
+2
Business Services, Science and Engineering, Health and Medical

20-30

https://antagtherapeutics.com/

Glasgow, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

2-10

https://www.aurumbiosciences.com/

Geneva, Switzerland

Information Technology
+4
Information Technology, Health and Medical, Business Services, Professional Services, Science and Engineering

10-20

http://www.isc-sa.ch/isc-light-therapy-expert-2/

300/480 results

Frequently asked questions

Updated 23 October 2026

What is Enterprise League?

Enterprise League is a free business directory that helps buyers find the right company by sector and country. Every company has a profile showing what it does, what it offers and how to get in touch.

Is it free to list my company?

Yes, and it stays free: no card, no paid tier. Your profile appears in search results and category pages, can show up to 20 products and services, and lets buyers message you or ask for a quote.

How does verification work, and what does it cost?

Verifying your company is free. Confirm a code we email to an address at your company’s website, or send a company registration document for our team to check, and the verified badge appears on your profile. To show the badge in the directory and search results as well, take out a subscription: the first 14 days are free, and the price is on our pricing page.

Where does the company information come from?

Most profiles are built from public sources, such as official company registers. Claim your company’s profile to correct its details and add your own.

How do I claim or correct my company’s profile?

Open your company’s profile and choose Claim Profile. If you use an email address at your company’s website, a 6-digit code makes the profile yours at once; otherwise our team reviews your request, usually within a few days. Spotted a mistake on a company that isn’t yours? Tell us through our contact page.